Another OTHER one bites the dust!
Another convalescent plasma trial for Covid-19 goes bust.
In an NIH funded trial, of 500 patients, results showed
Covid-19 progression occurred in 77 patients (30%) in the convalescent plasma group and in 81 patients (31.9%) in the placebo group. In other words, stuff all real difference!
https://endpts.com/outpatient-use-o...nt-covid-19-progression-new-nejm-study-finds/
In the NIH funded MSB trial which was of people with MORE ADVANCED disease [ie, MSB was stopping end-stage ARDS, NOT merely "disease progression"] - results showed a 75% reduction in mortality in COVID-19 ARDS patients under 65. With the company now exploring options for dose increase [in size and number of treatments] for those 65+.
If the USFDA is a truly "professional body" there is simply no reason to further delay and not APPROVE MSB in the ARDS space!
Growing REAL Evidence MSB ARDS Should be Approved NOW!
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.015(1.40%) |
Mkt cap ! $1.241B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.12 | $1.08 | $11.51M | 10.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 58289 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 467665 | 27 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.015 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.12 | $1.08 | 1937390 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| MSB (ASX) Chart |